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Outcome comparisons by prescribable treatment options. Mor- individual components of the dialysis treatment, pre-
tality and morbidity of hemodialysis patients results from a scribe these separately and thereby control quality [2].
number of factors, some of which are potentially under the The wide use of the urea reduction ratio (URR) [3, 4]control of the nephrologist. Dialysis dose is the most important
is explained by its simplicity, but the inability to prescribeof these factors, but other comorbid factors have been identi-
from or for it has limited its practical value. The URRfied. These include attainment of appropriate hemoglobin con-
centrations, good nutrition, control of calcium and phosphorus measurement has been of value for epidemiologic stud-
metabolism, lipids, and blood pressure, as well as less quantita- ies, but it is less useful in the care of individual patients
tive factors such as psychological well-being and patient-physi- because of significant margins of error. Corrective equa-cian contact. However, other factors outside the nephrologist’s
tions that take into account ultrafiltration volumes, gen-control also affect morbidity and mortality, particularly with
eration of urea and body size, reduce the error of therespect to multi-organ damage that can occur if renal replace-
ment therapy is not started early in the course of renal disease. URR but do not provide specific information concerning
This paper seeks to outline many of the factors that affect volume or protein catabolic rate. [5]. Depending on
morbidity and mortality.
whose interpretation is accepted, results from the NCDS,
which did not control adequately for the dose of dialysis,
suggested at the time a standard for Kt/V of ,0.9–1.0,
The mortality and morbidity of hemodialysis patients below which morbidity increases gradually or abruptly.
is to a large extent determined by demographics and by As experience was gained with the application of the
existing comorbidities but it is obvious that variations in
single pool Kt/V following recommendations made by
treatment characteristics (i.e., those prescribed by the
expert panels and the issuance of practice guidelines,
nephrologist and executed by the dialysis team) have
the relationship between dose and mortality could be
substantial effects. In addition, the geography of the dial-
analysed and high doses were recommended [6]. Theysis facility and local or regional environmental and fac-
shape of the curve relating dose to mortality has beentors influences may influence outcomes. Table 1 shows
much discussed [7]. What seems certain is the steepnessa list of major prescribable treatment characteristics.
of the slope with Kt/Vs lower than ,1.0–1.1. Dialysis
Outcomes Quality Initiative (DOQI) guidelines recom-
mend a single pool Kt/V of 1.3, allowing for errors orDIALYSIS DOSE
compliance problems in delivering the recommendedNo other dialysis-related topic has provoked as much
dose of at least 1.2 [8]. It is axiomatic that a well-dialyzeddiscussion as the clearance of small molecules required
population is best described by the percentage of patientsfor an adequate dose of dialysis. The National Coopera-
that reach or exceed a predetermined level rather thantive Dialysis Study (NCDS) reports analyzed this ques-
the mean dose [9]. Whether more dialysis is better, whention by focusing on the concentration of urea nitrogen
dialysis is provided three times a week, has been much(time averaged) rather than on its removal [1]. This em-
debated. Undoubtedly lower mortality is reported byphasis was misinterpreted and misused by many who did
Laurent and Charra, who use much higher Kt/Vs fornot understand the dual influences of generation and
most of their patients, but other factors such as betterremoval of urea on the concentration of the latter. The
fluid removal and compliance, lower blood pressures,insights of Sargent and Gotch in formulating and devel-
and the effect of lower regional death rates in the generaloping the concept of fractional clearance of urea in rela-
population also affect outcome [10].tion to volume (Kt/V) made it possible to examine the
There is a gradual movement in the U.S. towards use
of the equilibrated Kt/V (double pool, eKt/V) as the
Key words: hemodialysis, dialysis dose, mortality, morbidity. preferred measure of the delivered dose of dialysis rather
than the single pool. Since the post-dialysis rebound is 2000 by the International Society of Nephrology
S-105
Levin: Outcomes by treatmentS-106
Table 1. Possible factors affecting outcomes time nephrologists spend with their patients on dialysis.
Some evidence suggests that increased time may corre-1. Dose of dialysis
2. Time spent with patients late with improved survival (when appropriately ad-
3. Nutrition justed) [14]. Definition of medically useful as opposed4. Psychological status and patient satisfaction
to “social” time is difficult. Despite these problems, it5. Water treatment
6. Membrane flux (permeability) seems obvious that more physician contact would facili-
7. Time on dialysis tate the detection of early problems and could not be8. Frequency of dialysis
anything but beneficial. The ability to provide this degree9. Phosphorus control
10. Anemia control of service is influenced by economic considerations to
11. Blood lipids different extents, but physician assistants or specifically12. Exercise and improvement in the activities of daily living
trained nurse clinicians might provide a solution when13. Intradialytic symptoms
14. Drug related problems nephrologist energy is utilized elsewhere [15]. Dr. Clau-
15. Dialyzer reprocessing dio Ronco has advocated the formula MDt/P as being16. Vascular access
comparable in importance to Kt/V, where MDt is physi-17. Withdrawal from dialysis
cian time and P 5 patient [16].
NUTRITIONdirectly related to the ratio of clearance to volume, dial-
ysis dose is likely to be overestimated by single pool Currently, the National Kidney Foundation (NKF)-
measures in small people treated with short dialysis DOQI is writing practice guidelines for nutrition in adult
times, particularly when using large dialyzers at high and pediatric dialysis patients. With reference to the
blood flows. Since small people on dialysis may be at subject of this paper, i.e., prescribable factors, this sub-
increased risk of poor survival, utilizing eKt/V is of even stantial effort deals, inter alia, with recommendations for
greater importance. Rate equations are being used to levels of intake of protein and of calories that produce
estimate eKt/V in the HEMO Study, since waiting 30–60 the lowest mortality and morbidity; whether carnitine
min for blood drawing after the end of dialysis is hardly supplementation is useful; the possible role of growth
practicable [11]. Any method of assessing the delivered hormone therapy; and whether vitamin or mineral sup-
dialysis dose requires standardized methods of blood plementation improves outcomes.
drawing that eliminate recirculations (both access and Protein intakes of 1–1.2 g/kg daily and caloric intakescardiopulmonary) and variable rebound. Utilizing the
of 32–35 kcal/kg daily are the current cornerstones ofslow flow/stop pump sampling technique accomplishes
nutritional therapy for dialysis patients, but the problemsthis [12]. The National Institutes of Health HEMO
associated with anorexia have not been satisfactorilyStudy, now in its third year, will provide definitive infor-
solved. Intradialytic parenteral nutrition is limited (bymation on dose vs. a variety of outcome measures [13].
regulation in the U.S.) to patients with demonstrableeKt/Vs of 1.05 and 1.45 are being compared, as is also
major disease of the gastrointestinal tract that prohibitsthe permeability (flux) of the dialyzer membranes.
absorption. This approach can improve weight, particu-Monthly comparisons of the measurement of V (total
larly by adding body fat [17]. Low body mass indexbody water) permits quality control evaluation of deliv-
measured at the initiation of dialysis is an independentered treatments. After accumulating the values of 3 Vs
indicator of increased mortality [18].differing by an average of no more than 15%, any subse-
While the serum albumin concentration is consideredquent Vs that are markedly different are a stimulus for
investigation. The urea kinetic software computer pro- to provide information concerning nutrition in dialysis
grams in common use interpret a reduction in the deliv- patients and is a powerful indicator of outcome, recent
ery of the dose as a larger V. When V is apparently information concerning the negative effect of chronic
increased, search for causes such as reduced dialyzer inflammation on hepatic albumin synthesis and on appe-
clearance or decreased dialysis times is required. Simi- tite shifts attention to the pathogenesis and possible
larly, a smaller V is interpreted by the software to indi- treatment of the factors involved. Consequences of
cate that more treatment than prescribed has been given. chronic inflammation include reduction in albumin syn-
This apparent increase could be a result of incorrect thesis—the effects of which may eventually cause an-
drawing of the blood sample at the end of a treatment orexia and tissue loss—increasing atherogenic risk fac-
in which there is significant recirculation thus reducing tors, epoetin resistance, increase in polymorphonuclear
the arterial blood urea concentration. neutrophil counts, reduction in creatinine, pre-albumin,
increase in fibrinogen, reduction in voluntary activity,
TIME SPENT WITH PATIENTS and increase in whole body protein catabolism. From a
therapeutic point of view, it is possible that parenteralOne of the more direct aspects of dialysis treatment
that has received surprisingly little attention is how much nutrition could be useful in the presence of malnutrition
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associated with chronic inflammation. Could feeding glu- raised C-reactive protein levels. The authors demon-
cose and amino acids be effective in reducing effects of strated that these phenomena could be significant risk
anorexia even in the presence of inflammatory inhibition factors for accelerated atherogenesis [29].
of albumin synthesis?
Oxidative stress occurs as the end result of many
WATER TREATMENTpathological processes during chronic dialysis including
The Association for the Advancement of Medical In-chronic inflammation, infection, and poor membrane
strumentation (AAMI) writes standards for water, dial-biocompatibility. In one large, recent series, the survival
ysis machines, dialyzers, and reprocessing of dialyzers,of overweight patients was significantly better than those
etc., which are accepted in the U.S. by the federal govern-that were underweight [19]. Reproducible measurements
ment and utilized by international standard organiza-of the results of oxidant stress, e.g., oxidation of lipids
tions. The relevant AAMI committee has recently sug-and proteins, and formation of advanced glycation end
gested a reduction in the acceptable level of endotoxinproducts, can be made available [20, 21]. Systematic long-
in water to be used for dialysis to 2 Endotoxin Unitsterm examination of the effect of antioxidants such as
(Eu/mL) from the previous level of 5 Eu. Some Euro-vitamins E and C, lipoic acid, and selenium on outcomes
pean and Japanese standards are even stricter. No com-are required. The role of chronic inflammation in causing
parative trials have been performed on the long termoxidative stress requires clarification, as does the link
effect of such a change, but use of “ultrapure” waterbetween immunologic function, levels of circulating cyto-
obtained by passing treatment water through a polysul-kines and survival [22]. Blood levels of homocysteine are
fone or polyamide dialyzer, acting as an endotoxin filter,increased, sometimes markedly, in ,30–40% of dialysis
has resulted in claims of better outcomes and of a lowerpatients [23], and these levels are associated with in-
incidence of dialysis amyloidosis due to b2-microglob-creased risks of cardiovascular disease. High doses of
ulin [30].folic acid, possibly also requiring cofactors such as vita-
min B12 and vitamin B6, can reduce homocysteine concen-
trations in 30%–50% of hyperhomocysteinemic patients
MEMBRANE FLUX (PERMEABILITY)[24]. Long-term outcome information concerning reduc-
Despite the undoubted value of utilizing a definedtion is not yet available.
Kt/V for urea as the indicator of adequate dialysis of
small molecules for improving survival, removal of larger
ATTEMPTS TO IMPROVE PSYCHOLOGICAL molecules bestows further benefits [31]. The identity of
STATUS AND PATIENT SATISFACTION many dialyzed (and non-dialyzed) substances is not
The importance of psychosocial factors, such as lower known, and the quantitation or clearance of small pro-
levels of social support, decreased compliance, and nega- teins and other middle molecules is not routinely per-
tive perception of the effects of illness, have been admira- formed. In general, the volumes of distribution and ki-
bly demonstrated by Kimmel [25]. It is noteworthy that netics of these substances are not well described. Ho¨rl
those factors are as quantitatively important as the bet- has described a series of proteins that are homologues
ter-recognized medical indicators of outcomes. In most of normal proteins and that accumulate in uremia [32,
dialysis units, psychosocial problems are not well treated 33]. While there is uncertainty as to which substances
and few resources are available. Social workers to patient are relevant, high flux dialysis is associated with improve-
ratios are often low, and organized clinical psychological ments in survival when adjustments are made for Kt/V
or psychiatric care is rare. In addition to the beneficial and demographic factors [34]. The role of biocompatibil-
effect of dealing with adverse psychosocial factors, it is ity in reducing morbidity is less clear, although benefits
possible that the high rates of voluntary withdrawal from have been claimed independent of removal of larger
dialysis in the U.S. might be reduced by more compre- molecules [35].
hensive care [26]. Measures of patient satisfaction are
now being incorporated as a regular part of the evalua-
TIME ON DIALYSIStive process of patient care, particularly spurred on by
Duration of treatment is a contentious subject. Thethe stimulus of health maintenance organizations. The
dialysis world is divided into two camps supporting eitherShort Form 36 Health Care Questionnaire (SF36) in
longer or shorter times, with the definition of each ratherparticular has been well validated as a tool for evaluating
cloudy. The early argument for long treatment time,mental and physical activity categories in the dialysis
when cellulosic dialyzers were used, was the increasedpopulation. Patients’ views of their treatment is also a
removal of middle molecules (in the range of ,1000 D)stimulus for improvement [27, 28]. A recent cross-sec-
with longer dialysis times but the advent of high fluxtional study in patients with chronic renal failure demon-
strated high anti-1G anti-chlamydia titer in patients with dialyzers with higher sieving coefficients disposed of this
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concept since these dialyzers removed more of a much reduced epoetin requirements, improvement in blood
pressure control, improvement in left ventricular hyper-larger range of molecular weight substances than could
the earlier dialyzers, however prolonged dialysis was. trophy and increased patient satisfaction [39, 40–42]. A
dialysis terminology to convert all dialysis doses to aHowever, even with current high flux dialyzers, it is likely
that removal rates of larger molecules ($12000 D) will standard at Kt/V dose, i.e., to make it possible to com-
pare dialysis schedules of different frequencies, has beenbe greater with longer dialysis times.
A better argument for prolongation of dialysis times developed [43]. The standard Kt/V utilizes the ratio of
generated urea to peak urea level and equates all dialysisis the ability to remove fluid weight gains more smoothly
and to a greater degree. Experience with daily dialysis doses to continuous therapy. A Kt/V of 2.0 for peritoneal
(see below) suggests that better control of blood pressure dialysis is modeled to be equivalent to an eKt/V of 1.0,
is obtained, possibly due to better removal of salt and 33 per week. Equivalent weekly Kt/V for daily dialysis
water [36]. However, the favorable effect on blood pres- would be between 2.0 and 3.0. The more frequently dial-
sure is not seen immediately in some patients, and there- ysis is given, the more it approaches continuous therapy.
fore Charra and colleagues have consistently maintained Consequently, it is not surprising that lower Kt/Vs, when
that dry weight and with it blood pressure can be reduced dialysis is given daily, result in as much solute removal
by regular ultrafiltration over 8 h. Initially, patients are as apparently higher Kt/Vs when given 33 per week.
symptomatic with cramps and hypotension, but later While economically impractical in the U.S. under current
have few problems and have excellent blood pressure reimbursement methods, capitation, particularly global,
control without drugs [35]. These authors have consis- could well change current views about dialysis, since
tently ascribed the excellent survival of their patients patient outcomes appear to be so good. Whether treat-
to slow, long dialysis. On the other hand, Gotch and ments should be given for 2–3 hours daily or whether
Uehlinger have published low mortality figures in pa- long nocturnal treatments are necessary is a decision
tients dialyzed for a mean period of only 2.5 h [37]. that will be made eventually on outcome measures, eco-
The need to relate ultrafiltration rates to hypotensive nomics and quality of life.
symptoms is unquestioned. Patients with the common
condition of diastolic dysfunction respond to rapid rates
PHOSPHORUS CONTROLof ultrafiltration with marked reduction in cardiac output
Increased serum phosphorus levels, Ca 3 P productand hypotension, making this an important factor in de-
(driven mainly by phosphorus) and increased PTH levelstermining dialysis time. A recent publication comparing
are associated with increased mortality, mainly due toSwedish and Tassin dialysis methods concludes that it is
cardiovascular causes [44, 45]. Dialysis performed 33possible to ultrafilter the same volume equally well with
weekly is not usually effective in the control of serumshort and long dialysis times with similar normal blood
phosphorus, the major factors being dietary intake andpressures. Long dialysis appears to markedly reduce the
the use of phosphate binders. More effective bindersneed for antihypertensive drugs. Whether the situation
with greater patient acceptance have been developedwould be the same in the U.S., where hypertension as
[46]. Whether cardiac damage may be ameliorated byan apparent cause of renal failure is much more common,
phosphorus control earlier in the course of renal failureparticularly in African Americans, is questionable; the
and whether sudden death may be prevented by anti-use of antihypertensive drugs in most U.S. dialysis units
arrhythmic drugs requires investigation.may be inescapable [26].
A reasonable synthesis of the argument concerning
dialysis time would suggest that most patients can be ANEMIA CONTROL
dialyzed quickly, but that others must have longer dial-
The cardiovascular, cognitive and quality of life im-ysis times to preserve hemodynamic stability [38]. Qual-
provements following increases in hemoglobin as a resultity of life issues may have to be balanced against the
of appropriate use of epoetin and iron are well describedneed for antihypertensive drugs. The HEMO Study did
[47]. The importance of reaching a minimum hemoglobinnot include time as one of its controlling variables, but
of 10–11 g/dL has been appropriately emphasized. How-a secondary analysis of the study may permit an assess-
ever, some controversy exists as to whether normaliza-ment of the question of time.
tion of hemoglobin may be deleterious in patients with
coronary artery disease [48]. While the results in Bes-
FREQUENCY OF DIALYSIS arab’s paper are open to a variety of interpretations,
the rheology of the coronary, cerebral and peripheralFrom both the theoretical and practical points of view,
it appears that more frequent dialysis is accompanied by vascular circulation in the presence of atherosclerotic
plaques and increased hematocrit (as during rapid ultra-better control of blood chemistries, decreased hospital-
ization, increases in serum albumin, gains in body mass, filtration) requires study. The effects of intravenous iron,
Levin: Outcomes by treatment S-109
as measured by its oxidant effects, also require clarifica- of blood volume refilling rates have been suggested as
tion, in terms of both total dose given and in rate of another way of determining the dry weight [53, 54]. Ini-
administration. tially, it was thought that a particular degree of blood
volume change would reproducibly be associated with
hypotension, but this has not been substantiated. The
BLOOD LIPIDS
response of the sympathetic nervous system in compen-
Risk factors for increased mortality in the general pop- sating for decreased blood volume is critical to mainte-
ulation such as increased low density lipoprotein (LDL), nance of blood pressure. However, sympathetic response
decreased high density lipoprotein (HDL), increased may be a double-edged sword, in that the predominance
LP(a), and possibly increased triglycerides, suggest that of cardiac-sympathetic activity as opposed to parasympa-
use of drugs that reverse these changes may be useful thetic activity could be a source of cardiac arrhythmias
in dialysis patients. Total cholesterol is usually not in- and sudden death [55, 56]. Beta-blocker drugs may be
creased; paradoxically, low cholesterol (in this case due useful in controlling this problem and are probably un-
to malnutrition) is an indicator of mortality. 3-Hydroxy- derused in the dialysis population. Therapeutic re-
3 methylglutaryl-coenzyme A (HMG-CoA) reductase sponses to hypotension include dialysate cooling and the
inhibitors are probably the drugs of choice in this popula- use of midodrine to maintain a vasconstrictive response
tion given their success in the general population. Ap- [57, 58].
proaches to hyperlipidemia based on diet alone are
unlikely to be successful; therefore, drug therapy, de-
pending on the level chosen, will be preferable. The NKF DRUG-RELATED PROBLEMS
Task Force Report on Cardiovascular Disease recom- As pointed out recently, patients on dialysis are at
mends the treatment of patients with raised LDL ($130) substantial risk for the development of drug-related
in patients with cardiac disease [49]. Treatment of such problems [26, 59]. On average these patients receive
patients would be a substantial undertaking since ,30% 8–14 drugs, and interactions, duplications, inappropriate
of patients are so affected. At least as reported thus far, dosing, and adverse reactions are common. The clinical,
few dialysis units are systematically treating hyperlipid- quality of life, and financial burdens are not accurately
emia in this fashion. Reduction in triglycerides by dietary known, but related problems may cost the health care
change or drugs is of uncertain benefit. Some high flux system billions and contribute substantially to hospital
biocompatibile membranes have been shown to favor- admissions. Utilization of nephrologically orientated
ably affect abnormal lipid concentrations [50].
clinical pharmacists would go a long way towards dealing
with this important, but largely neglected, problem.
EXERCISE AND IMPROVEMENT IN THE
ACTIVITIES OF DAILY LIVING
DIALYZER REPROCESSING
The April 1999 issue of Advances in Renal Replace-
The safety of certain methods of dialyzer reprocessingment Therapy, under the editorship of Patricia Painter
has been questioned in two large analyses of the Healthand Kristen Johansen, is devoted to the philosophy,
Care Financing Administration (HCFA) database [60, 61].methodology and outcomes of exercise and rehabilita-
After corrections for comorbidities increased death ratestion management in dialysis patients [51]. While ne-
and hospitalizations were still demonstrable in reuseglected in most facilities at present, there is increasing
facilities. These two databases agree in suggesting in-awareness of the possible physiological and physical ben-
creased mortality with use of a peracetic acid–aceticefits of this approach. The objective of such a program
acid–hydrogen peroxide mixture in patients dialyzed inshould be to improve the status of almost every patient
freestanding dialysis units. As this phenomenon did notrather than concentrating on increasing fitness in the few
occur in hospital-based units, the problem could be adialysis athletes to be found in most dialysis facilities.
procedural one rather than a deficiency of the sterilantA favorable effect of exercise on reducing atherogenic
itself. Dialyzer reprocessing is still very popular in thecytokines has recently been reported [52].
U.S., but there is a move for the first time in many years
towards non-reuse. If manufacturers can produce large
INTRADIALYTIC SYMPTOMS high flux dialyzers that are competitive in cost with that
of the reprocessed dialyzer, and since there is little medi-Reduction of blood volume by ultrafiltration during
cal advantage of reuse with current standard methods,dialysis is accompanied by unpredictable physiological
current reuse practices will change. One argumentresponses, so that the same rate of ultrafiltration on
against some methods of reuse is decreased dialyzerdifferent days may be accompanied by hypotension on
one day and by stable blood pressure on another. Use clearances, especially of large molecules [62].
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VASCULAR ACCESS after these and the other components of the prescription
have been identified, it is clear that mortality and morbid-NKF-DOQI guidelines and much European literature
ity are dependent on a variety of other factors over whichmake clear that the arteriovenous (AV) fistula is the
the nephrologist and the dialysis team have little control.preferred access for hemodialysis. While for some pa-
Reduction in mortality and morbidity is largely depen-tients and for U.S. methods of dialysis blood flows may
dent on beginning therapy early in the course of renalbe too low with some fistulae, a majority of patients are
disease since multi-organ damage is already demonstra-potentially suitable for this procedure if they are seen
ble in most patients at the beginning of renal replacementearly enough and plans made appropriately. A complex
therapy. These comorbid factors clearly limit survival onmatrix of access to nephrology care especially in the
dialysis and exert a negative effect on transplant survival.poor, referral patterns and reimbursement issues stand
Current research into states of chronic inflammation,in the way of the higher standards needed. NKF-DOQI
uremic toxins, and their more efficient removal by adsor-has led to improved recognition of the importance of
bents of different types, control of dialytic symptoms,monitoring methods for detection of access failure. This
better access methods and monitoring of access functionincludes static and dynamic pressure measurements, re-
are likely to add further improvements in dialysis patientcirculation, access flow measurements by different meth-
outcome. Since symptoms and morbidity are at leastods and Doppler visualization.
in part associated with the actual dialysis procedure,The role of access type and site on cardiac dysfunction
technical improvements in dialysis could also improverequires further elucidation. High flows associated with
the efficacy of treatment.high cardiac outputs, particularly in proximal fistulae,
may be harmful in patients who already have cardiac
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